Business Description
Alaunos Therapeutics Inc
NAICS : 325412
SIC : 2834
ISIN : US98973P1012
Share Class Description:
TCRT: Ordinary SharesDescription
Alaunos Therapeutics Inc is a clinical-stage cellular immuno-oncology company dedicated to the treatment of solid tumors through adoptive TCR-T cell therapy. It strikes cancer at its core by engineering cell therapies that target Neoantigens arising from genomic mutations.
Financial Strength
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 5.18 | |||||
| Equity-to-Asset | 0.76 | |||||
| Debt-to-Equity | 0.19 | |||||
| Debt-to-EBITDA | -0.04 | |||||
| Piotroski F-Score | 4/9 | |||||
| Altman Z-Score | -161.81 | |||||
| Beneish M-Score | 36.31 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | -72.6 | |||||
| 3-Year EPS without NRI Growth Rate | -69.1 | |||||
| 3-Year FCF Growth Rate | -81.3 | |||||
| 3-Year Book Growth Rate | -64.3 |
Momentum Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 58.76 | |||||
| 9-Day RSI | 44.8 | |||||
| 14-Day RSI | 41.27 | |||||
| 6-1 Month Momentum % | 23.77 | |||||
| 12-1 Month Momentum % | -76.67 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 4.22 | |||||
| Quick Ratio | 4.22 | |||||
| Cash Ratio | 3.1 | |||||
| Days Sales Outstanding | 219 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -3.8 | |||||
| Shareholder Yield % | 107.41 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Operating Margin % | -569860 | |||||
| Net Margin % | -702800 | |||||
| FCF Margin % | -606780 | |||||
| ROE % | -159.84 | |||||
| ROA % | -103.84 | |||||
| ROIC % | -208.61 | |||||
| ROC (Joel Greenblatt) % | -313.04 | |||||
| ROCE % | -142.83 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 264 | |||||
| PB Ratio | 3.38 | |||||
| Price-to-Tangible-Book | 3.38 | |||||
| EV-to-EBIT | -0.38 | |||||
| EV-to-EBITDA | -0.4 | |||||
| EV-to-Revenue | 2502.4 | |||||
| EV-to-Forward-Revenue | 4293.85 | |||||
| EV-to-FCF | -0.41 | |||||
| Price-to-Net-Current-Asset-Value | 3.38 | |||||
| Price-to-Net-Cash | 5.08 | |||||
| Earnings Yield (Greenblatt) % | -263.16 | |||||
| FCF Yield % | -143.56 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:TCRT
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Alaunos Therapeutics Inc Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 0.005 | ||
| EPS (TTM) ($) | -2.29 | ||
| Beta | -2.06 | ||
| Volatility % | 169.68 | ||
| 14-Day RSI | 41.27 | ||
| 14-Day ATR ($) | 0.167717 | ||
| 20-Day SMA ($) | 1.4715 | ||
| 12-1 Month Momentum % | -76.67 | ||
| 52-Week Range ($) | 0.659999 - 10.469999 | ||
| Shares Outstanding (Mil) | 16.01 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Alaunos Therapeutics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Alaunos Therapeutics Inc Stock Events
| Event | Date | Price($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Alaunos Therapeutics Inc Frequently Asked Questions
What is Alaunos Therapeutics Inc(TCRT)'s stock price today?
The current price of TCRT is $1.32. The 52 week high of TCRT is $10.47 and 52 week low is $0.66.
When is next earnings date of Alaunos Therapeutics Inc(TCRT)?
The next earnings date of Alaunos Therapeutics Inc(TCRT) is 2024-05-10 Est..
Does Alaunos Therapeutics Inc(TCRT) pay dividends? If so, how much?
Alaunos Therapeutics Inc(TCRT) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers